Ocaliva (obeticholic acid) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES: IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP				
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
□ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):				

Prime THERAPEUTICS*

Continued on next page.

Ocaliva (obeticholic acid) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR	
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
□ Primary biliary cholangitis (PBC, formerl □ Other diagnosis:			
3. REQUIRED CLINICAL INFORMATION	I: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A	
PRIOR AUTHORIZATION.			
Clinical Information:			
Is Ocaliva being prescribed by or in co	ensultation with a hepatologist or gastro	penterologist? Yes No	
Has the patient had an inadequate re	sponse to ursodeoxycholic acid (UDCA)	for at least one year? ☐ Yes ☐ No	
Will the patient be taking Ocaliva con	currently with ursodeoxycholic acid (UI	DCA)? □ Yes □ No	
·	to tolerate ursodeoxycholic acid (UDCA	•	
	to tolerate disodeoxycholic acid (ODCA	ij! 🗆 fes 🗆 No	
Reauthorization:			
If this is a reauthorization request, an	<u> </u>	and an arranged to the second	
improvement with both of the follow	positive clinical response to treatment	as demonstrated by patient	
□ Serum alkaline phosphatase (ALP) o	=		
1	mg/dL for females and less than 1.5mg	/dl for males	
	cords (e.g. chart notes, laboratory value		
	nsultation with a hepatologist or gastro		
Are there any other comments, diagn	oses, symptoms, medications tried or fa	ailed, and/or any other information the	
physician feels is important to this re-	view?	•	
Please note: Not all drugs/diagnosis a	re covered on all plans. This request may	be denied unless all required	
information is received.		·	
ATTESTATION: I attest the informatio	n provided is true and accurate to the be	est of my knowledge. I understand that	
	p or its designees may perform a routine	•	
information necessary to verify the ac	curacy of the information reported on th	nis form.	
Prescriber Signature or Electronic I.D.	Verification:	Date:	
	companying this transmission contain confidentia		
	reby notified that any disclosure, copying, distribu I have received this information in error, please n		

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management LLC Attn: CP - 4201 P.O. Box 64811

St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.